Julia Lawrence

1.8k total citations
31 papers, 1.3k citations indexed

About

Julia Lawrence is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Julia Lawrence has authored 31 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Julia Lawrence's work include Chemotherapy-induced cardiotoxicity and mitigation (5 papers), Cancer-related cognitive impairment studies (4 papers) and Cancer Treatment and Pharmacology (4 papers). Julia Lawrence is often cited by papers focused on Chemotherapy-induced cardiotoxicity and mitigation (5 papers), Cancer-related cognitive impairment studies (4 papers) and Cancer Treatment and Pharmacology (4 papers). Julia Lawrence collaborates with scholars based in United States, United Kingdom and Spain. Julia Lawrence's co-authors include Craig A. Hamilton, Ralph B. D’Agostino, Leslie R. Ellis, Susan A. Melin, Jennifer H. Jordan, W. Gregory Hundley, Patricia S. Steeg, William C. Little, Frank M. Torti and Debra Weinstat‐Saslow and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Julia Lawrence

30 papers receiving 1.3k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Julia Lawrence 656 594 294 279 271 31 1.3k
Courtney L. Bickford 510 0.8× 892 1.5× 213 0.7× 208 0.7× 203 0.7× 6 1.2k
Von Hoff 540 0.8× 221 0.4× 66 0.2× 171 0.6× 295 1.1× 39 1.1k
Joanna M. Brell 1.2k 1.8× 134 0.2× 89 0.3× 502 1.8× 422 1.6× 40 1.7k
Tammy F. Chu 461 0.7× 635 1.1× 86 0.3× 280 1.0× 328 1.2× 6 1.0k
Michael P. Chu 570 0.9× 81 0.1× 156 0.5× 246 0.9× 308 1.1× 66 1.2k
Jérôme Alexandre 823 1.3× 103 0.2× 68 0.2× 528 1.9× 360 1.3× 100 1.7k
Javier Gómez 361 0.6× 180 0.3× 75 0.3× 373 1.3× 270 1.0× 51 1.0k
Omar Y. Mian 200 0.3× 101 0.2× 73 0.2× 269 1.0× 385 1.4× 85 907
Maria Laura Canale 204 0.3× 551 0.9× 116 0.4× 209 0.7× 175 0.6× 77 895
Weihua Li 371 0.6× 112 0.2× 107 0.4× 506 1.8× 351 1.3× 74 1.0k

Countries citing papers authored by Julia Lawrence

Since Specialization
Citations

This map shows the geographic impact of Julia Lawrence's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia Lawrence with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia Lawrence more than expected).

Fields of papers citing papers by Julia Lawrence

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia Lawrence. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia Lawrence. The network helps show where Julia Lawrence may publish in the future.

Co-authorship network of co-authors of Julia Lawrence

This figure shows the co-authorship network connecting the top 25 collaborators of Julia Lawrence. A scholar is included among the top collaborators of Julia Lawrence based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia Lawrence. Julia Lawrence is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wagner, Andrew J., Jonathan C. Trent, Steven Attia, et al.. (2024). Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology. 42(16_suppl). 11533–11533. 1 indexed citations
3.
Heinrich, Michael C., Neeta Somaiah, Jonathan C. Trent, et al.. (2024). Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology. 42(3_suppl). TPS766–TPS766. 1 indexed citations
4.
Weaver, Kathryn E., et al.. (2019). Preferences for breast cancer survivorship care by rural/urban residence and age at diagnosis. Supportive Care in Cancer. 28(8). 3839–3846. 1 indexed citations
5.
Lawrence, Julia, Laura D. Baker, Ernie Balcueva, et al.. (2017). National Institute on Aging /Alzheimer’s Association criteria for Mild Cognitive Impairment applied to chemotherapy treated breast cancer survivors. PubMed. 1(1). 1–19. 7 indexed citations
6.
Tawfik, Bernard, Timothy S. Pardee, Scott Isom, et al.. (2015). Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). Journal of Geriatric Oncology. 7(1). 24–31. 50 indexed citations
7.
Danhauer, Suzanne C., Leah Griffin, Nancy E. Avis, et al.. (2015). Feasibility of implementing a community-based randomized trial of yoga for women undergoing chemotherapy for breast cancer. The Journal of Community and Supportive Oncology. 13(4). 139–147. 16 indexed citations
8.
D’Agostino, Ralph B., Julia Lawrence, Craig A. Hamilton, et al.. (2014). Chronic Statin Administration May Attenuate Early Anthracycline-Associated Declines in Left Ventricular Ejection Function. Canadian Journal of Cardiology. 31(3). 302–307. 86 indexed citations
9.
Drafts, Brandon C., Ralph B. D’Agostino, Julia Lawrence, et al.. (2013). Low to Moderate Dose Anthracycline-Based Chemotherapy Is Associated With Early Noninvasive Imaging Evidence of Subclinical Cardiovascular Disease. JACC. Cardiovascular imaging. 6(8). 877–885. 280 indexed citations
10.
Lawrence, Julia, Steven A. Akman, Susan A. Melin, L. Douglas Case, & Gary G. Schwartz. (2013). Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer. Cancer Biology & Therapy. 14(6). 476–480. 19 indexed citations
11.
Tawfik, Bernard, Susan Lyerly, Heidi D. Klepin, et al.. (2013). Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Annals of Hematology. 93(1). 47–55. 46 indexed citations
12.
Kimple, Randall J., Janet K. Horton, Chad Livasy, et al.. (2012). Phase I Study and Biomarker Analysis of Lapatinib and Concurrent Radiation for Locally Advanced Breast Cancer. The Oncologist. 17(12). 1496–1503. 12 indexed citations
13.
Vern-Gross, T.Z., Julia Lawrence, L. Douglas Case, et al.. (2012). Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery. Journal of Neuro-Oncology. 110(3). 381–388. 44 indexed citations
14.
Colonna, Sarah V., L. Douglas Case, & Julia Lawrence. (2011). A retrospective review of the metabolic syndrome in women diagnosed with breast cancer and correlation with estrogen receptor. Breast Cancer Research and Treatment. 131(1). 325–331. 21 indexed citations
15.
Chaosuwannakit, Narumol, Ralph B. D’Agostino, Craig A. Hamilton, et al.. (2009). Aortic Stiffness Increases Upon Receipt of Anthracycline Chemotherapy. Journal of Clinical Oncology. 28(1). 166–172. 112 indexed citations
16.
Kamel, Dia, et al.. (2009). Late cutaneous metastases to the face from malignant pleural mesothelioma: A case report and review of the literature. World Journal of Surgical Oncology. 7(1). 84–84. 13 indexed citations
17.
Lawrence, Julia, et al.. (2008). Current Therapeutic Options for Breast Cancer Central Nervous System Metastases. Current Treatment Options in Oncology. 9(1). 41–50. 1 indexed citations
18.
Klein, Pamela & Julia Lawrence. (2002). Lavage and nipple aspiration of breast ductal fluids: A source of biomarkers for environmental mutagenesis. Environmental and Molecular Mutagenesis. 39(2-3). 127–133. 12 indexed citations
19.
Freije, José M.P., Julia Lawrence, Melinda G. Hollingshead, et al.. (1997). Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines. Nature Medicine. 3(4). 395–401. 30 indexed citations
20.
Weinstat‐Saslow, Debra, Maria J. Merino, Richard E. Manrow, et al.. (1995). Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Medicine. 1(12). 1257–1260. 270 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Courtney L. Bickford Breakdown of academic impact, for papers by Von Hoff Breakdown of academic impact, for papers by Joanna M. Brell Breakdown of academic impact, for papers by Tammy F. Chu Breakdown of academic impact, for papers by Michael P. Chu Breakdown of academic impact, for papers by Jérôme Alexandre Breakdown of academic impact, for papers by Javier Gómez Breakdown of academic impact, for papers by Omar Y. Mian Breakdown of academic impact, for papers by Maria Laura Canale Breakdown of academic impact, for papers by Weihua Li
Rankless by CCL
2026